BioSpace News Archive

This week, leadership from the U.S. Food and Drug Administration, the U.S. Customs and Border Protection (CBP), and the U.S. Immigration and Customs Enforcement, Homeland Security Investigations (ICE-HSI) signed a Memorandum of Understanding (MOU) to stop harmful products that pose a threat to public health and attempt to enter the U.S. through International Mail Facilities (IMFs).

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, announced today that results from two pivotal Phase 3 studies evaluating setmelanotide in proopiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity were published in The Lancet Diabetes & Endocrinology.

The IDMC also recommends continuation of enrollment in the REGN-COV2 outpatient trial Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patie

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the Chicago Tribune’s Top Workplaces 2020 , ranking number two out of other midsize companies in the Chicago area. “Receiving the Top Workplaces award is especially meaningful for us because the Chicago area is home to our U.S. headquarters,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “With a significant

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced it has been named one of the global biopharmaceutical industry’s top employers in Science and Science Careers’ 2020 Top Employers Survey for the sixth consecutive year. Moderna was ranked 9th on the list this year and

Consortium brings together world-class and globally coordinated clinical development, commercialization, cGMP manufacturing, and logistics expertise to accelerate the deployment and availability of Avigan® tablets for the potential treatment and prevention of COVID-19

Potential first-in-class treatment for hypertrophic scars with no FDA-approved medicines to to-date Phase 2a trial follows the successful completion of OliX’s Phase 1 trial in the U.K. in November 2019 OliX retains global rights to develop and commercialize OLX10010 outside Asia

The Government of Canada is committed to protecting the health and safety of all Canadians while ensuring economic resilience and contributing to the international response to COVID-19. Since the outbreak of COVID-19, the government has been working closely with industry to understand which areas require urgent investment while building dome

In response to the second wave of COVID-19 in Canada and the risk it represents for the mental health and well-being of working populations, EQ Care is recognizing the immediate needs of needs of the Canadians

BioAgilytix is thrilled to announce the addition of a new diagnostics tool to their growing list of cutting-edge bioanalysis instruments. The Phadia™ 200 is a powerhouse of a machine, in a compa